TP53 and cancer: Among these patients, 167 (7.8%) harbored concurrent KRAS and TP53 hotspot mutations (KRAS+/TP53+ mutant cancer), 182 (8.5%) harbored KRAS+/TP53– hotspot mutations, and 839 (39.1%) harbored KRAS–/TP53+ hotspot mutations (- indicates negative hotspot test).